Liprimar 10 mg - nā ʻōlelo aʻoaʻo no ka hoʻohana

Ka puka ʻana o Liprimar - nā papa: elliptical, i kāwili ʻia me ke membrane kiʻi ʻoniʻoni ʻo ke keʻokeʻo, ma kahi wāhā - ʻano nui o ke kala keʻokeʻo:

• Me ke kahakaha "10" ma kekahi ʻaoʻao a me PD "155" ma kekahi (10 pcs. I nā poli, ma kahi kāwele kāleka he 3 a 10 mau laha paha).
• Me ke kiʻi "20" ma kahi a me PD "156" ma kahi ʻē aʻe (10 pcs. In blisters, in a cardboard bundle of 3 or 10 blisters),
• Me ka hana ʻana i ka "40" ma kekahi ʻaoʻao a me PD "157" ma kekahi (10 pcs. In blisters, 3 blisters in a cardboard box),
• Me ke kālai 'ana "80" ma kekahi ʻaoʻao a me PD "158" ma kekahi (10 pcs. In blisters, in a cardboard bundle 3 blisters).

Aia i kēlā me kēia papa pākuʻu:

• ʻO ka papa hana: atorvastatin (ma ke ʻano o ka paʻakai kalaiʻa) - 10, 20, 40 a i ʻole 80 mg,
• ʻO nā mea kōkua: nā sodium croscarmellose, magnesium stearate, lactose monohidate, microcrystalline cellulose, calcium carbonate, hyprolose, polysorbate,
• ʻO ka mana o ke kaomi palani: opadry keʻokeʻo YS-1-7040 (candelil wax, titanium dioxide, polyethylene glycol, talc, hypromellose, simethicone emulsion (stearic emulsifier, sorbic acid, simethicone, wai)).

Nā hōʻailona no ka hoʻohana ʻana

Ka hopena o nā maʻi aʻe:

• ʻO ka hypercholesterolemia mua (heterozygous familial a non-familial hypercholesterolemia (type IIa e like me ka helu o Fredrickson),
• Famertial endogenous hypertriglyceridemia (type IV ma ke ʻano o Fredrickson), kū i kaʻai,
• ʻO Dysbetalipoproteinemia (ʻano III e like me ka helu ʻana o Fredrickson) (ma ka hoʻohui i ka ʻai),
• Ua hui ʻia nā ʻano hyperlipidemia (IIa a me IIb e like me ka helu ʻana o Fredrickson),
• ʻO ka Homozygous familial hypercholesterolemia (hoʻohana ʻia ka lāʻau lapaʻau i ka hihia inā ʻaʻole i lawa ka pono o ke ʻano non-pharmacological o ka papa mālama, me ka mālama ʻana i ka ʻai).

Hoʻolālā ʻia ʻo Liprimar no nā pale pale:

• ʻO ka pale mua ʻana o nā hoʻopiʻi cardiovascular ma nā maʻi me ka ʻole o nā hōʻailona o ka maʻi naʻau coronary, akā me kekahi mau mea e pili ana i ka hoʻomohala ʻana: ʻoi aku ʻo 55 mau makahiki he 55 mau makahiki, ka ulaula, diabetes mellitus, hypertension arterial, predisposition genetic, hoʻemi haʻahaʻa haʻahaʻa o ke kiʻekiʻe lipoprotein kūloko (HDL-C) i ka plasma,
• Ka pale ʻana i ka hoʻopiʻi ʻana o nā hoʻopiʻi cardiovascular ma nā mea maʻi me ka maʻi puʻuwai coronary i mea e hōʻemi ai ka hōʻemi ʻana o ka angina pectoris, stroke, myocardial infarction, make, me ka pono no ka revascularization.

Nā Hoʻohui

• ʻO ka maʻi maʻi ate a i ʻole ka hana o nā transaminases hepatic i ʻike ʻole ʻia (ʻoi aku ma mua o 3 mau manawa i hoʻohālikelike ʻia i kēlā me congenital adrenal hyperplasia).
• Ke lalo o 18 mau makahiki
• Kahawai
• Lactation (a i ʻole ka ʻohi ʻana e hoʻokipa)
• Hypersensitivity i nā ʻāpana o ka lāʻau.

Pili (mālama pono)

• He mōʻaukala mahele o ka puʻuwai,
• Ka inu maikaʻi ʻana i ka waiʻona.

ʻLoe a me ke kākele

Ma mua o ka hoʻomaka ʻana iā Liprimar, pono ia e hoʻokō i ka hoʻopaʻa o ka hypercholesterolemia me ke kōkua o ke kau ʻana i ka papa ʻaina, ke ʻano kino a me ka hoʻolilo ʻana i ke kaumaha ma nā mea maʻi me ka maʻi nui, me ia hoʻi ma o ka mālama ʻana i ka maʻi kumu.

Pono ʻia ka lālani i ke koina i ka manawa 1 i kēlā me kēia lā i kahi manawa o ka lā, me ka mālama ʻole o ka meaʻai.

Hiki ke loli ka pā helu i kēlā me kēia lā mai 10 a 80 mg. Ke koho nei ke kauka i ka ʻikepili e noʻonoʻo ana i nā hōʻike, ka ʻike mua o ka lipoprotein cholesterol low-density (LDL-C) a me ka hopena therapeutic o Liprimar.

Ma ka maʻamau o ka hypercholesterolemia a me ka hyperlipidemia hui pū ʻia, kahi laʻe o kēlā me kēia lā i lawa no ka hapa nui o nā maʻi he 10 mg. Hōʻike ʻia ka hopena therapeutic i loko o 2 mau pule, hiki i ka lōʻihi ma hope o nā 4 wiki.

Me ka hypercholesterolemia ʻohana homozygous, ʻōlelo pinepine ka lāʻau i loko o kēlā me kēia lā o 80 mg.

ʻO ka poʻe maʻi me ka maʻi hepatic e hoʻemi i ka maʻa o ka Liprimar ma lalo o ka mālama mau ʻana i ka hana o alanine aminotransferase (ALT) a me ka aspartate aminotransferase (AST).

Pono ka mea maʻi e hoʻopiʻi i ka ʻai hypocholesterolemic maʻamau i ʻōlelo ʻia e ke kauka ma o ka manawa mālama.

I kēlā me kēia mau pule he 2-4 i ka hoʻomaka ʻana o ka hoʻōla a ma kēlā me kēia pane e pono ai, pono ia e hoʻomalu i nā maʻi lipid i ke koko a hoʻoponopono i ka maʻi inā pono.

Inā hui pono i ka mālama ʻana me ka cyclosporine, ʻaʻole pono ka nui o ke koʻi o Liprimar i ka 10 mg.

Nā hopena hopena

Basically, ke hoʻomanawanui maikaʻi ʻia ka lāʻau lapaʻau. ʻO nā hopena o ka ʻaoʻao, inā hele mai lākou, he mau liʻiliʻi liʻiliʻi a me kahi ʻano transient.

Hiki paha nā hopena ʻino:

• ʻO nā ʻōnaehana o ka waena: pinepine (≥1%) - pilikia o ka maʻi, ka ʻōpū, ka asomyic syndrome, ʻeha (≤1%) - dizziness, hypesthesia, paresthesia, malaise, peropheral neuropathy, amnesia,
• Pūnaehana digestive: pinepine - ʻeha o ka ʻōpū, ʻiliʻī, dyspepsia, nausea, ke nānā ʻana, constipation, i ʻole nā ​​loi - hoʻopuka, jaundice cholestatic, pancreatitis, hepatitis, anorexia,
• Pūnaehana musculoskeletal: pinepine - myalgia, ʻaʻole liʻiliʻi - myositis, nā mākala o ka naʻau, myopathy, rhabdomyolysis, ʻeha hoʻi, arthralgia,
• Hematopoietic ʻōnaehana: luhi - thrombocytopenia,
• Metabolism: luhi - hyperglycemia, hypoglycemia, hoʻonui i nā kiʻekiʻe o ka serum creatine phosphokinase,
• He maʻi kūloko: ʻaʻole - kaʻili, ka ʻupena o ka ʻili, urticaria, rash bullous, necrolysis epidermal toxic, erythema multiforme, kūmole anaphylactic,
• ʻO kekahi: paʻakikī - nā ʻehaʻeha, ka impotence, hoʻonui i ka momona, ka nui o ka momona, tinnitus, alopecia, ka hopena o ka renal lua, ka edema peripheral.

Nā ʻōlelo kikoʻī

E like me nā lipid-haʻahaʻa haʻahaʻa o ka papa like, hiki i ka Liprimar ke hoʻopilikia i ka hana o nā enzymes o nā aʻalolo. No kēia kumu, ma mua o kona koho ʻia, ma hope o 6 a me 12 mau pule ma hope o ka hoʻomaka ʻana o ka hoʻohana ʻana, i kēlā me kēia piʻi pālua, me ke ʻano hoʻi o kēlā me kēia manawa o ka mālama ʻana, pono ia e nānā i nā ʻanā hana maʻamau. Pono ke aʻo ʻana i nā hana ate ma ka mea ʻo nā lāʻau lapaʻau o kona hōʻino. Inā hoʻonui kekahi hana i ka hana ALT a i ka AST ma mua o 3 mau manawa i hoʻohālikelike ʻia me ka hōʻailona like no ka congenital adrenal hyperplasia, pono e hoʻemi ʻia ka lāʻau a i ʻole e hoʻopau i ka lāʻau lapaʻau.

Aia nā lono e pili ana i nā hihia hopohopo o ka rhabdomyolysis, i hele pū me ka hana ʻole o ka renal i hiki ai ma ka myoglobinuria, i nā mea maʻi e lawe nei iā Liprimar. No kēia kumu, inā he hopena koʻikoʻi o ka hiki ʻole o ka renal ma muli o ka rhabdomyolysis (e like me ka maʻi nui aʻeha o ka maʻi, ka trauma, ka nui ʻana o ka maʻi, ka hypotension arterial, endocrine, electrolyte a me ka hoʻokalakupua o ka hoʻokalakupua, nā kaʻe hoʻokō ʻole) a inā i ʻike ʻia nā hōʻailona e hiki ke hoʻohana i ka manaʻo e hopohopo i ka myopathy. Pono liprimar e hoʻopau iki a hoʻomaha paha.

Pono e hōʻike ʻia nā maʻi āpau e pono koke lākou e ʻike i ke kauka i ka nāwaliwali a i ʻole ka hōʻeha ʻana o ka ʻeha puʻuwai, inā hoʻi pū me lākou i ka maʻi a me ka malaise paha.

Hiki ke kuhikuhi ʻia nā wahine o ka hānau hānau ʻana inā ʻo Liprimar wale nō inā e hōʻemi ʻia ka hopena o ka hapai, a ʻike ʻia ka poʻe maʻi e pili ana i nā hopena kūpono. Pono ka wā mālama holoʻokoʻa e hoʻohana i nā ala kūpono o ka contraception.

ʻAʻole ʻike ka ʻike i ka hopena o ka atorvastatin ma ke ʻano o ka hopena a me ka ʻike.

Hoʻohui nūhou

Me ka hana like o nā fibrates, cyclosporins, ka waikika nikotinic i nā dosis hypolipidemic, clarithromycin, erythromycin a me nā ʻaina antifungal e kumulima o ka azole, piʻi ka ulu ʻana o ka hoʻomohala i ka myopathy.

Hoʻopili ka Atorvastatin i ka isoenzyme CYP3A4, no laila, nā mea paʻa o kēia isoenzyme (me ka clarithromycin, itraconazole a me ka erythromycin, diltiazem) hiki ke hoʻonui i ka ulu ʻana o ka atorvastatin i loko o ke koko koko.

Pono e noʻonoʻo i ka wai o ka hua māla ua loaʻa i ka mea liʻiliʻi i hoʻokahi mea e pale ai i ka isoenzyme CYP3A4, no laila ka nui o ka hoʻohana (ma mua o 1,2 lita i kēlā me kēia lā) hiki ke alakaʻi i ka piʻi ʻana o ka atorvastatin i ke koko.

Hiki i nā mea hoʻohālikelike o ka cytochrome CYP3A4 isoenzyme (no ka laʻana, efavirenz a me rifampicin) hiki ke hoʻohaʻahaʻa i ka plasma plasma o ka atorvastatin. Inā e pono, e hoʻohana i ka manawa like i rifampicin, ʻelua mau lāʻau e hoʻokaʻawale ʻia, ka lohi ana i ka lawelawe ʻana o ka liprimar ma hope o ke rifampicin e alakaʻi i kahi nui o ka pae o ka atorvastatin i ke koko.

OATP1B1 inhibitors (no ka laʻana, ʻo ka cyclosporine) hiki ke hoʻonui i ka bioavailability o atorvastatin.

Me ka hoʻomohala like ʻana o nā antacids e loaʻa ana i ka alumini a i ʻole hykano hydroxide, ke emi nei ke kahe ʻana o ka atorvastatin e pili ana i ka 35%, akā ʻaʻole pili kēia i nā pae o ka hōʻemi o ka pae LDL-C.

Hoʻololi ʻo Colestipol i ka hoʻoulu ʻana o ka atorvastatin i ka plasma ma kahi o 25%, eia naʻe, ʻoi aku ka hopena lipid-lowing o ka hoʻohana ʻana i kahi ʻano like ʻole i nā hopena o ka lawe kaʻawale i kēlā me kēia lāʻau lapaʻau.

Inā pono, ʻo ke koho ʻana iā Liprimar i ka manawa like me ka digoxin e koi aku i ka mālama ʻana i nā lāʻau lapaʻau.

Ke koho ʻana i kahi kuhi waha wahaheʻe no kahi wahine e hoʻomaʻamaʻa ana me Liprimar, pono e noʻonoʻo ʻia ka nui o ka atorvastatin hoʻonui i ke kahe o ka ethinyl estradiol a me ka norethisterone (ma kahi o 20% a 30%, kēlā me kēia).

Liprimar: nā ʻōlelo aʻoaʻo no ka hoʻohana

E nānā i ke wikiō:

Liprimar: mau loiloi

Ma ka Pūnaewele hiki iā ʻoe ke ʻike i nā loiloi o nā loiloi e pili ana iā Liprimar. Ua kaulana kēia mau penikala, ʻoiai me kā lākou uku kiʻekiʻe. I ka manawa e kākau ai ka poʻe i nā loiloi ma nā papa atorvastatin ʻē aʻe (Atoris, Torvacard), ʻōhumu pinepine lākou no ko lākou hopena. ʻO nā loiloi e pili ana i ka lāʻau Liprimar i piha i nā hoʻopiʻi kūpono e pili ana i ke kumukūʻai kiʻekiʻe. Akā aneane ʻaʻole kahi o nā mea kākau e hoʻopiʻi i nā hopena ʻaoʻao.

Ua maopopo ka poʻe i ka wā e lawe ai lākou i ka lāʻau lapaʻau nui loa i kā lākou kulana, ʻaʻole ia e loaʻa nā hopena. Ma kahi o ke koho ʻana i ka lālani Liprimar, ʻoi aku ka analogues haʻahaʻa - Atoris, Torvakard a i ʻole - hoʻopiʻi nā mea maʻi.Eia nō naʻe, manaʻoʻiʻo lākou i mua e loaʻa i nā lāʻau ʻalaʻawa ke ʻoi aku nā hopena ʻē aʻe. ʻOiai maoli nō ʻaʻole kēia. ʻO ka hapa nui o nā hopena pā o nā statins i ʻōiwi i ka loiloi o nā loiloi ma muli o nā kumu noʻonoʻo, aia ma mua o nā hopena maoli o nā lāʻau.

Nui nā loiloi e kākau ʻia e nā poʻe e lawe i ka atorvastatin ma hope o ka infococose myocardial. Ke ola nei i ka puʻuwai naʻau, ʻaʻole pili ka poʻe e hoʻopakele i kā lākou mālama. Makemake lākou e kūʻai i nā lāʻau lapaʻau loa loa, ʻo ia hoʻi ʻo Liprimar. Kēia, ua mākaukau nā poʻe liʻiliʻi e uku a hoʻolilo kālā i ko lākou olakino i ke keʻena o ka pale ʻana, ke hiki ke pale ʻia a hōʻeha paha. E heluhelu i nā loiloi kikoʻī o nā maʻi e lawe ana i ka Liprimar.

Nā nīnau a me nā pane nīnau

ʻO nā pane aʻe i nā nīnau i kū pinepine i nā maʻi.

Pehea ka lōʻihi e lawe ai iaʻu i ka Liprimar?

E like me nā statins ʻē aʻe, pono ʻia ʻo Liprimar i kēlā me kēia lā, i ke koena o kou ola, inā he ʻehaʻeha i mua o ka ʻā ʻana a i ʻole ka pāpaha puʻuwai e hōʻeha nei, me ka ischemic stroke. Heluhelu i ka manaʻo nui ma statins a ʻike i ka mea e pono ke lawe i kēia mau lāʻau a ʻaʻole hoʻi. ʻAʻole ʻoe e lawe i nā wā hoʻomaha i ka lawe ʻana i nā lāʻau kolamu ma ka mea i kuhikuhi ai. Lawe iā lākou i kēlā me kēia lā i ka manawa like.

ʻO Liprimar, e like me nā statins ʻē aʻe, hiki ke hōʻeha i ka ʻeha, ka ʻeha ma nā ʻāʻī a me nā hana. No ka ʻike hou aku, e ʻike i ka ʻatikala "ʻaoʻao o nā statins." Eia naʻe, hoʻomāhuahua ka lōʻihi o kēia lāʻau lapaʻau i ke ola, e hōʻemi i ka hopena o ka hoʻoulu mua a me ka hana pinepine ʻana i ka naʻau. No laila, hiki i kāna hana maikaʻiʻole ke hōʻemi i ka hōʻemi a me ke kaumaha. Inā hiki i ka atorvastatin i nā pilikia koʻikoʻi, a laila neʻe ka haki i loko o kāna intake ke kōkua ʻole. Ma hope o ka hoʻomaha ʻana, ʻoi aku ka hopena o ke ʻano e hoʻi hou. ʻO nā mea maʻi e ʻike i nā hopena ʻaoʻao hiki ʻole ke kamaʻilio pū me ko lākou kauka i ka hōʻemi o ka nui, ke hoʻololi ʻana i kekahi lāʻau lapaʻau hou, a i ʻole pau ʻana o nā statins.

ʻAʻole lawe ʻia ka liprimar i kēlā me kēia lā. ʻAʻole ia i hoʻāʻo ʻia i kēlā me kēia regimen. ʻAʻole hiki iā ia ke pale iā iā ia mai kahi hōʻiliʻili puʻuwai. Kauka ʻia nā kauka i kākau ʻia e lawe i atorvastatin a i ʻole nā ​​statins i kēlā me kēia lā i loko o nā "hana hana." ʻOi aku ka maikaʻi o ka hoʻololi i kekahi kauka i kahi loiloi ʻoihana ʻoi aku. Inā 'ae ʻoe i ka mālama ʻana me nā papa liprimar ma mua, a laila e lawe iā lākou i kēlā me kēia lā. A inā he hewa, e kūkākūkā me kāu kauka e hana.

Hiki iaʻu ke hoʻokaʻawale i kahi papa ma ka hapalua?

ʻAʻole hiki ke hoʻokaʻawale ʻia nā papa liprimar. ʻAʻohe kahi hoʻohele ʻokoʻa ma luna o lākou. Ka hana ʻole - hiki iā ʻoe ke kaʻana, akā ʻoi aku ka maikaʻi ke hana. Ma ka home, ʻaʻole hiki iā ʻoe ke hoʻokaʻawale i ka papa ma ka hapalua, ʻoi me ka pahi ʻoi, a ʻoi aku ka nui me ka pahi. ʻO ka hopena, ʻo kēlā me kēia lā ʻoe e lawe i nā ʻano like ʻole o ka lāʻau lapaʻau e hoʻohaʻahaʻa i ka kolesterol "maikaʻi". Hoʻomaopopo kēia i nā hopena o ka mālama ʻana.

E hoʻomanaʻo i kahi ʻano maʻi o atorvastatin 5 mg i kēlā me kēia lā ʻaʻole i loiloi ʻia i loko o kekahi mau haʻawina haʻawina. Loaʻa paha, ʻaʻole ia e pale i ka nui o ka hoʻouka ʻana me ka hoʻomaka mua ʻana. No laila, ʻaʻole ʻoe e kaʻana i kahi papa 10 mg e lawe i ka 5 mg no ka lā. ʻO kekahi poʻe, ke hoʻāʻo nei e mālama i ke kālā, kūʻai i nā pōpoki e loaʻa ana nā dosis kiʻekiʻe o Liprimar. A laila mahele ʻia kēlā mau papa i ka hapalua a lawa ko kēlā me kēia maʻa no 2 mau lā. ʻOi aku ka maikaʻi ke hana i kēia i ʻole ka like o ka lāʻau o ka lāʻau lapaʻau āu e lawe nei i kēlā me kēia lā.

E nānā pū i ke wikiō "Cholesterol Statins: ʻAoʻi Pilikino."

Hiki iā ʻoe ke ʻālana i nā analogues o Liprimar i mea maʻalahi?

ʻO Liprimar kahi lāʻau lapaʻau mua o ka atorvastatin. I ʻike ʻia no ke kūlana kiʻekiʻe, akā ka mea kūʻai aku ke kiʻekiʻe. Inā hiki iā ʻoe ke pili, a laila e koho i nā lāʻau lapaʻau mua no ka mālama ʻana a mai mālama i kā lākou analogues. Eia naʻe, ʻo ka uku kiʻekiʻe e hana i ka hoʻomākaukau no nā maʻi cardiovascular ke hiki i ka hapa nui o nā maʻi. I kēia hihia, ʻo ka koho maikaʻi loa e pili ana i nā tapa o nā papa Liprimar, aia i loaʻa ma ʻEulopa ʻEulopa. ʻO kēia ʻo Atoris, Torvakard, Tulip a i ʻole.

ʻO nā mea hoʻomehana Cheaper i nā papa atorvastatin i hana ʻia i ka Lūkini Lūkini a me nā ʻāina CIS. Hoʻohana ʻia lākou e ALSI Pharma, Canonfarm Production, VERTEX a me nā mea ʻē aʻe. Ua aʻo ʻia e kahi cardiologist akamai e pale aku iā lākou, e heluhelu hou aʻe ma aneʻi. E makemake i nā papa atorvastatin e hana ʻia ma ka Repubalika Czech, Slovenia a me nā ʻāina ʻē aʻe o ka Hikina ʻEulopa. ʻAʻole kūpono ia he lawe i nā lāʻau lapaʻau neʻe ʻia mai India.

ʻO Liprimar aiʻole atorvastatin: ʻoi aku ka maikaʻi?

ʻO Liprimar kahi lāʻau lapaʻau mua nona nā mea kanu ikaika i ka atorvastatin, hana ʻia e Pfizer. Ua manaʻo ʻia o ke kūlana kiʻekiʻe loa ma waena o nā hoʻomākaukau hoʻomākaukau atorvastatin. ʻO nā papa āpau ʻē aʻe i loaʻa i ka atorvastatin kona mau analogues (generics). ʻO nā mea maʻi e makemake nei e lawe i ka lāʻau maikaʻi loa atorvastatin e koho iā Liprimar. No kēlā me kēia pahu i kēlā mau kumukūʻai, pono ʻoe e uku i kahi nui o ke kālā. Inā makemake ʻoe e hoʻopakele, a laila e hoʻolohe pono i ka hoʻomākaukau o atorvastatin, aia ka poʻe i loaʻa ma Eastern Europe. Ua wehewehe ʻia lākou i ka kikoʻī o ka pane i ka nīnau i hala.

ʻO Liprimar aiʻole rosuvastatin: ʻoi aku ka maikaʻi?

E like me kāu e ʻike nei, ʻo ka mea ikaika o nā papa liprimar he atorvastatin. A ʻo ka rosuvastatin he lāʻau hou hou no ka cholesterol ma mua o ka atorvastatin. Hoʻonui hou aku ia i ka koloka LDL "hewa" i ke koko o nā mea maʻi, ʻoiai inā i kuhikuhi ʻia ma nā haʻahaʻa haʻahaʻa. Akā ʻoi aku ke aʻo ʻia ʻo atorvastatin, no ka mea he lōʻihi aku ia. E heluhelu i ka ʻatikala kikoʻī ma ka rosuvastatin, ka loulou e hāʻawi ʻia ma luna nei. E ʻike ma loko o ka mea i ʻoi aku ka maikaʻi - atorvastatin a rosuvastatin.

Ke hoʻohana nei nā kānaka i nā statins e hoʻomaikaʻi i kā lākou helu koko kolamu, me ka hōʻemi ʻana i ka mana o ka hoʻomaka mua a me ka lua o ka puʻuwai puʻuwai. Inā e lawe ʻoe i Liprimar a kōkua iā ʻoe iā ʻoe, a laila ʻaʻole i manaʻo iki ka hoʻololi ʻana i ka rosuvastatin wale nō no ka mea he lāʻau hou. Eia nō naʻe, i kekahi poʻe, ʻaʻole lawa ka atorvastatin i ka cholesterol kino LDL "hewa". I kēia hihia, pono ʻoe e nīnau i ke kauka inā he pono ke hoʻololi i ka rosuvastatin, e hana ikaika ana. ʻAʻole e hoʻololi i kāu papa ponoʻi i kekahi lāʻau lapaʻau no ka kolala no kekahi. Hana nō i kēia me ke ʻae ʻia o kāu kauka.

ʻO Liprimar a i Atoris: kahi ʻoi ke lāʻau maikaʻi?

ʻO Liprimar ka lāʻau lapaʻau mua o ka atorvastatin, a ʻo Atoris ʻo ia ka analogue (generic). ʻO Liprimar, e like me nā lāʻau lapaʻau mua, ka mea i manaʻo ʻia i ke kūlana kiʻekiʻe loa ma kāna pūʻulu. Akā, inā ʻaʻole hiki iā ʻoe, no laila e mālama pono iā Atoris. Kuhi ʻia kēia mau papa atorvastatin e ka hui kaulana ʻo KRKA ma ʻEulopa ʻEulopa e like me nā kūlana o EU. ʻO ka Atoris kahi hui o kūpono kūpono a me ke kiʻekiʻe.

ʻO Liprimar a i ʻole Torvacard: ʻo wai ka lāʻau lapaʻau ʻoi aku ka maikaʻi?

ʻO Torvacard kahi lāʻau lapaʻau ʻo Zentiva atorvastatin. hoʻokūkū ʻia me nā papa Atoris, i kūkākūkā ʻia no ka pane ʻana i nā nīnau o mua. ʻOi aku ka maikaʻi o Liprimar ma mua o Torvacard. Akā inā ʻaʻole hiki ʻole ke kumukūʻai o ka lāʻau maoli no mākou, a laila ʻo Torvacard kahi koho maikaʻi. Loaʻa ʻia kēia lāʻau lapaʻau i ka Czech Republic. E wehewehe i ka ʻāina mai ka mea i loaʻa i ka paina ma ka pa. ʻAʻole ʻoe e ʻike i kahi ʻike hilinaʻi ma nā wahi āpau e ʻoi aku ka maikaʻi - Atoris a i Torvakard. ʻO kēlā me kēia mau lāʻau maikaʻi nā analogue atorvastatin. E waiho i ke koho ma waena o lākou ma ka ʻae o kou kauka.

Ua hoʻonui ke kauka i kaʻu nui o nā papa liprimar mai 10 a 40 mg i kēlā me kēia lā, no ka mea kiʻekiʻe ka cholesterol. Hopohopo e pili ana i nā hopena ʻaoʻao.

E aʻo i kahi ʻōmole C-reactive, a e kiaʻi pono loa i kēia kuhikuhi ma mua o ka "maikaʻi" a me ka "maikaʻi" cholesterol. E hoʻohuli paha ua lawa nā haʻahaʻa haʻahaʻa o nā statins i koe.

Hiki i ka atorvastatin ke hōʻeha i nā wāwae, ke aloʻi ʻana, a i ʻole hoʻi kaʻe i nā wāwae, mau lima?

ʻO kēia mau hōʻailona āpau e hiki ke lilo i ka hopena o Liprimar a me nā statins ʻē aʻe. ʻO ka mea mua, lawe i nā hoʻokaʻina koko a me nā urine e hoʻomaʻamaʻa i kou hana o ka maʻa. Inā hoʻohuli ʻo ia nā mea āpau i nā maʻi maʻamau, a laila e lawe i ka magnesium-B6 mai nā wāwae kaohi. Tingling a ʻāʻī paha i nā wāwae, puʻuwai - hiki i ke hōʻailona ke hoʻomohala nei ʻoe i ka maʻi diabetes. E ana i kāu kaila koko ma hope o ka ʻai ʻana (ʻaʻole ma ka ʻōpū ʻole!) Me kahi mita mika koko ʻōmaʻomaʻo a i ʻole ma kahi keʻena. Inā hoʻopaʻa ʻia ka maʻi diabetes, e aʻo pehea e mālama ai ia ma lalo o ka hoʻomalu ʻana ma aneʻi. I kēia hihia, pono ʻoe e kāpae i ka lawe ʻana i nā statins me ka ʻole o ke ʻae i ke kauka.

Hiki iaʻu ke inu i ka wai pia ke lawe nei ʻo Liprimar?

Inā ʻoe e hoʻopilikia i kahi waiʻona, ʻaʻole hiki iā ʻoe ke lawe iā Liprimar a i ʻole nā ​​statins ʻē aʻe. Inā he "mea i hoʻohui ʻia" kou mea inu, pono ʻoe e makaʻala - e lawe i ka lāʻau lapaʻau, akā hana pinepine i nā hoʻokaʻina koko no nā enzyme o ka pale a mālama i nā hōʻailona jaundice. E kūʻē i ka mua o ka mālama ʻana me ka atorvastatin, ʻae ʻia ka wai inu 2 i kēlā me kēia lā no nā kāne ma lalo o ka 65 a ʻo kekahi e lawelawe ana no nā kāne ma luna o 65 a me nā wahine i kēlā me kēia makahiki. ʻO ka mea lawelawe he 10-15 g o ka waiʻona maʻamau, i.e. kahi wai o ka pia, he aniani waina a i ʻole kahi ipu wai ikaika 40-degere. Inā ʻaʻole ʻoe hiki i ka mālama iki, ʻoi aku ka maikaʻi o ka hoʻopiha piha ʻana i ka waiʻona.

E heluhelu i nā pane i kekahi 22 i nīnau pinepine ʻia i ka ʻatikala "Statins: FAQ. Pane i nā nīnau o ka poʻe maʻi. "

ʻO ka hoʻohana nuiʻana i ka lāʻau Liprimar

ʻO Liprimar ka lāʻau mua loa o ka atorvastatin, kekahi o nā statins hou. Mālama kēia lāʻau lapaʻau i ke kolamu o ke koko. He hoʻohaʻahaʻa ia i ke kiʻekiʻe o ka LDL cholesterol "kino", a me ka triglycerides, a hoʻonui i ka "maikaʻi" HDL cholesterol. Ua hōʻike ʻo Atorvastatin i ka hana pono e pale ai i ka hoʻoulu mua ʻana a me ka puʻe ʻana i ka puʻuwai, ischemic stroke. No nā kikoʻī hou aku e ʻike i ka ʻatikala "Liprimar: 15 mau makahiki mau ke kūʻiʻo ʻia" i loko o ka puke ninaninau "Rational Pharmacotherapy in Cardiology" Helu 7/2011. ʻO ke kumu o kēia lāʻau lapaʻau e hōʻemi i ka leʻaleʻa e pono iā ʻoe ke hana i kahi maʻi hana e hoʻihoʻi i ka kahe koko i loko o nā moku i loaʻa i ka atherosclerosis.

ʻO nā hoʻokolohua haukapila o ka atorvastatin, i alakaʻi ʻia i ka makahiki 1996-2011, i ʻoi aku ma mua o ka 50,000 mau mea maʻi me nā maʻi maʻi: coronary heart heart, diabetes mellitus, arterial hypertension, myocardial infarction. Ua lawe nā ʻikepili āpau i ka ʻimi mua no Liprimar. Ua hōʻike ʻia kēia mau lāʻau he lāʻau lapaʻau maikaʻi a palekana hoʻi, no nā poʻe kahiko ka nui i hoʻonui i ka hopena o nā hopena ʻaoʻao. A ʻoi aku nā mea hou, no nā maʻi maʻi waena. ʻOi aku ka maʻalahi o ka hoʻomākaukau ʻana o Atorvastatin o nā mea hana ʻē aʻe, akā ʻaʻole lākou i kahi mau hōʻoia e hōʻoiaʻiʻo ʻia ana.

I nā ʻāina ʻōlelo Pelekānia, hoʻolaha ʻia ka hoʻomākaukau mua ʻana o ka atorvastatin ma lalo o ka inoa ʻo Lipitor. A hiki i ka makahiki 2012, a hiki i ka pau ʻana o ka patent, ua kūʻai ʻia no ka huina o ka astronomical - ʻoi aku ma mua o ka 125 miliona mau kālā. Ma nā ʻāina CIS, kapa like ka lāʻau lapaʻau ʻo Liprimar. I kēia manawa i loko o ka mākeke lāʻau lapaʻau ma waena o nā statins, ʻo ka hoʻokūkū nui ma waena o atorvastatin a me ka lāʻau lapaʻau hou - rosuvastatin. Ma lalo aʻe nei ua wehewehe ʻia i nā kikoʻī i nā hihia i ʻoi aku ka maikaʻi ma ke koho atorvastatin - ka lāʻau lapaʻau mua a i nā papa ʻē aʻe ʻē aʻe.

ʻO nā statins ka lāʻau maikaʻi loa i nā poʻe no ka hopena kiʻekiʻe o ka hōʻeha mua a me ka lua, me ka puʻu ischemic. Ma muli o ka hōʻemi nuiʻana i ka hōʻeha o ka catastrophe cardiovascular, lōʻihi ka lōʻihi. Hoʻomaikaʻi hou ka maikaʻi o ke ola inā ʻaʻole hopohopo nui ka mea maʻi ma nā hopena hopena. Ma nā ʻōlelo o ka hana pono no ka pale ʻana o ka hoʻoulu ʻana i ka naʻau a me ka hōʻeha ʻana, ʻaʻohe mea ʻē aʻe e hoʻohālikelike me nā statins. Atorvastatin kekahi o nā alakaʻi i waena o nā statins. Hoʻohana pinepine ʻia ka lāʻau lapaʻau mua ʻo Liprimar, ʻoiai naʻe i loaʻa nā papa liʻiliʻi atorvastatin mai nā mea hana ʻē aʻe i nā lāʻau lapaʻau.

Ke hoʻohaʻahaʻa nei i ka cholesterol "kino"

ʻO Atorvastatin kekahi o nā statins kaulana loa i ka honua a ma nā ʻāina e ʻōlelo nei ka Lūkia. Kuhi nā kauka i nā liprimar a i ʻole nā ​​papa atorvastatin e hoʻohaʻahaʻa i kā lākou kolamu LDL "maikaʻi" i ko lākou poʻe maʻi. Eia nō hoʻi, ke uku nei nā poʻe loea i ka hopena hou o kēia lāʻau lapaʻau i pili ʻole i ka kolamu. Ua kapa ʻia kēia mau hopena he pleiotropic. ʻO ka mea nui ka hoʻoemi ʻana i ka aʻa o ka maʻi palupalu i nā moku. Mahalo paha i ka emi ʻana o ka ulu ʻana o ka puʻuwai, hōʻeha, a me nā mea hanana "cardiovascular" kahi maʻi "i nā mea maʻi e pili pū ana me ka pleiotropic hopena o ka atorvastatin, a ʻaʻole me ka hoʻōlikelike ʻana o ka cholesterol.

Kūkulu ʻia ʻo Atorvastatin i loko o nā inika mai 10 a 80 mg i ka lā. ʻOi aku ka nui o ka maʻa i ka mea maʻi, ʻoi aʻe ia e hoʻohaʻahaʻa i ka kolamu LDL. Eia nō naʻe, me ka hoʻonui ʻana i nā pale, hoʻonui ka ulu ʻana o nā hopena ʻaoʻao. ʻO ka hoʻohaʻahaʻa nui o ka cholesterol LDL hiki i nā pilikia me ka noʻonoʻo a me ka hoʻomanaʻo. No ka mea he koʻikoʻi ka kolamu no ka lolo. ʻO ka pilikia o ke kaumaha, nā mea ʻeha kaʻa, a, paha, make kaʻi ʻana mai nā kumu a pau. E aʻo i ke kolamu koko no nā kāne a me nā wahine ma o nā makahiki. E kamaʻilio me kāu kauka e pili ana i ka maʻi kūpono o Liprimar.

ʻAʻole wale ʻo Atorvastatin e hoʻohaʻahaʻa i ka LDL, akā ke hoʻonui nei i ka pae o ka "maikaʻi" HDL kolamu. ʻAʻole pili kēia hopena i ka hewa o ka lāʻau lapaʻau. ʻO ka hoʻonui loa i kēlā me kēia lā o ka atorvastatin, ʻaʻole ia e koi i ka hoʻonui ʻia hou o ka neʻe o ka HDL kolamu i ke koko. E mālama i ka kolamu, triglycerides, a me ka coefficient kōlea atherogen, e huli i ka ʻai haʻahaʻa-kākeke. ʻO kēia ka mea e hōʻemi ai i ka lā maʻamau o Liprimar i 10-20 mg i kēlā me kēia lā a ʻole e hōʻole loa i ka mālama ʻana me nā statins.

Atherosclerosis

ʻO Atorvastatin, e like me nā statins ʻē aʻe, ke pale aku nei i ka hoʻomohala ʻana o ka atherosclerosis. Ma muli o kēia, ua hōʻemi ʻia ka pilikia o ka hōʻeha ʻana a me ka lua o ka puʻuwai, ischemic stroke, nā pilikia wāwae, ka makemake e hoʻihoʻi pono i ka kahe ʻana o ke kahe ma loko o nā ʻalā. Ua manaʻoʻiʻo ia i ka lāʻau Liprimar a me nā statins ʻē aʻe i kōkua i ke atherosclerosis, no ka mea e hōʻemi ana lākou i ka kolamu LDL. ʻO ka haʻahaʻa o ka kolamu o ka "bad" cholesterol, ʻoi aku ka mea e waiho ai i nā paia o nā ʻalihi i ke ʻano o ka pākeke.

Kahi manaʻo e nānā i ke ʻano - ʻo ka hopena nui ka hopena anti-inflammatory o nā statins. Inā e hoʻopau ʻoe i ke kani ʻana i ka maʻi ʻaʻai, a laila ʻaʻole e kaupalena ʻia ke kolikoli e nā radical manuahi. ʻO ka kolamu LDL, aia i kahi kūlana maʻamau, ʻaʻole i ka oxidized, ʻaʻole i waiho i nā paia o nā kīʻaha koko, ʻaʻohe mea nui e lele i loko o ke koko. ʻIa ka pae o ka hoʻonā kino ʻana i nā hopena o nā hōʻike o ke koko no ka protein C-reactive. No ka hōʻemi i ka kolesterol LDL "hewa" i kahi maʻamau, nā dosis kiʻekiʻe o ka atorvastatin, a i ka 80 mg i kēlā me kēia lā, pono paha. I ka manawa like, e hoʻomaikaʻi i ka hana o ka protein C-reactive, ʻoi loa ia e lawe i nā papa liprimar ma nā haʻahaʻa haʻahaʻa. E hoʻomaʻamaʻa pinepine ʻia no ka protein C-reactive, ʻaʻole wale no ka "maikaʻi" a me ka "maikaʻi" kolesterol.

ʻO Liprimar ka lāʻau mua loa ma waena o nā statins, no ka mea i hoʻāʻo ʻia e hōʻemi i ka nui o nā plak atherosclerotic. Ma hope mai, loaʻa ka waiwai like i ka rosuvastatin. Ma mua o ka paʻi ʻia ʻana o nā hopena noiʻi, manaʻoʻiʻo hiki hiki i nā stins ke hoʻolōʻihi i ka hoʻomohala ʻana i ka atherosclerosis, akā ʻaʻole lākou e pili i nā plak i kēia manawa. I mea e hoʻopau ai i ka nui o nā plak atherosclerotic, e hoʻohaʻahaʻa i ka lalo o LDL i ka 40% a i ʻole. No ka hanaʻana i kēia, e lawe i ka atorvastatin i loko o nā inika o 20 mg i kēlā me kēia lā a oi aʻe paha.ʻ recommendlelo aku nā ʻatikala ma nā papa kūkala olakino e kauka nā kauka i ka atorvastatin i ka lāʻau lapaʻau mua ma nā wahi a me nā kiʻekiʻe i nā mea maʻi, akā ʻaʻole i kaupalena ʻia no 10 mg i kēlā me kēia lā, ʻaʻole ia e kōkua nui.

ʻO ka mea kaumaha, me ka hoʻohana ʻana o ka atorvastatin a me nā statins no ka mālama ʻana i ka atherosclerosis, ʻaʻole maopopo nā mea āpau. Hōʻemi kēia mau lāʻau i ka waiho ʻana o nā kolamu ma nā pā o nā huawai. I ka manawa like, hoʻowalewale lākou i ka haʻalele ʻana o ka calcium i nā kīʻaha koko. Uʻi ʻia nā ʻalā me ke kīpē o ka calcium, a ʻaʻole loli, e like me ka maʻamau. Hoʻomaopopo kēia i kahi pae holomua o ka atherosclerosis. ʻO ka mea mua, ʻike ʻia nā palaka kolamu palupalu a a laila hoʻohui ʻia ka calcium kalapona iā lākou. ʻO Liprimar paha, e like me nā statins ʻē aʻe, e wikiwiki iā ia. E heluhelu i ka ʻatikala "Statins and Atherosclerosis" ma kahi kikoʻī. E aʻo pehea e pale aku ai i ka pani ʻana o ka paia arterial pale a me ka lohi ʻana.

ʻO ka maʻi ʻeha Coronary

ʻO nā poʻe i hōʻike ʻia i ka maʻi ʻeha coronary he mau maʻi nā mea maʻi kiʻekiʻe o ka cardiovascular. Pono lākou e lawe i ka liprimar a i nā papa atorvastatin ʻē aʻe ma ke ʻano o ka paʻakikī o nā lāʻau lapaʻau e kuhikuhi ai ke kauka. Loaʻa nā pōmaikaʻi o statins iʻoi aku ka kiʻekiʻe ma mua o ka hiki ke hōʻemi i nā hopena ʻaoʻao. E like me ʻoe e ʻike ai, ke kumu o ka maʻi naʻau coronary he coronary arteriosclerosis. Hoʻopili ke Atorvastatin i ka hoʻomohala ʻana o ka atherosclerosis a i ʻole e hōʻemi ana i ka nui o nā plaher atherosclerotic. Ma muli o kēia hopena, e hōʻemi i ka hopena o ka hōʻeha ʻana o ka naʻau a me ka puʻuwai, a me nā hōʻike ʻana o ka atherosclerosis o nā kīʻaha koko e holo ai ke koko i loko o ka lolo a me nā haʻahaʻa haʻahaʻa.

Ma ka papa moʻolelo Atherosclerosis a me Dyslipidemia ma 2013, ua paʻi ʻia ka ʻike ma nā hopena o ka mālama ʻana me ka atorvastatin i nā mea maʻi he 25 me kahi maʻi maʻi maʻi coronary heart.

Ua lawe ka maʻi āpau i ka atorvastatin-Teva 80 mg i kēlā me kēia lā. Hāʻawi ka lāʻau lapaʻau mua iā Liprimar i nā hopena like a i ʻole ka maikaʻi aʻe.

Me ka maʻi puʻuwai coronary paʻa, ʻaʻole hiki iā ʻoe ke holo wikiwiki e hana i ka hoʻokele a me ka coronary aren bypass hoʻokele, akā e hoʻāʻo mua e mālama ʻia i nā lāʻau lapaʻau, me nā koina kiʻekiʻe o ka atorvastatin. ʻO nā hōʻike e pili ana i nā haneli haneli ua hōʻoia i ka maikaʻi o kēia ala. E heluhelu pū i ka ʻatikala "Hōʻīaū i ka hōʻeha ʻana i ka puʻuwai a me kahi koʻokoʻo" a e hahai i nā pae i hōʻike ʻia ma laila. ʻO Atorvastatin i nā kiʻekiʻena ua hiki i nā mea he nui i nā ʻaina lapaʻau e pale ai i ka hoʻokō. Ma kēia mau noiʻi ʻana, ua hoʻāʻo wale ʻia ka Pfizer Liprimar kumu maoli. ʻAʻole ʻike ʻia inā hiki i nā papa atorvastatin mai nā mea hana'ē aʻe ke hāʻawi i ka hopena like.

Hoʻohālikelike nā haʻawina haole ma ka hopena o ka lāʻau lapaʻau a me ka hoʻomaʻamaʻa ʻana o ka maʻi naʻau coronary. Ka mea i hoʻololi ʻia i nā maʻi mau, ʻaʻole ka hōʻemi o ka hōʻemi i ka make a me ka hopena o ka pōʻino o catastrophe. Akā he mea nui ke kaʻina hana hoʻokipa, a nui ka maʻi ma ka make i ka papa ʻaina hana. ʻO ka hōʻike AVERT (Hoʻomaʻina Atorvastatin VErsus Revascularization) hōʻike ʻia ʻo ka lawe ʻana i nā papa liprimar o 80 mg i kēlā me kēia lā me ka mau lāʻau hou no 18 mau makahiki i hāʻawi i ka hopena ma mua o ka hana ʻana i nā maʻi IHD paʻa e hōʻemi loa i ka hōʻeha ʻana o ka naʻau. Ka mea i pono ke lapaʻau pono ka maʻi inā pono nā lāʻau lapaʻau e kōkua maikaʻi ʻole, a ma nā hihia koʻikoʻi. Ua paʻi hou ʻia nā hopena o ka noi ʻana o AVERT i ka makahiki 1999 a ua nui ka leo o nā kani. Eia nō naʻe, he nui nā mea maʻi me ka maʻi ʻalani coronary paʻa i nā mea e pono ai ʻole.

Ma hope o ka hoʻoili ʻia ʻana o ka naʻau

ʻO ka Atorvastatin a me nā statins ʻē aʻe e hoʻomaka koke ma hope o ka hōʻeha ʻana o ka puʻuwai puʻuwai. ʻO kēia ka mea e hōʻemi ai i ka loaʻa hou o ka infarction, hoʻomaikaʻi i nā hopena hōʻola. Ua kuhikuhi ʻia nā hoʻomākaukau Atorvastatin no nā poʻe maʻi i hōʻike ʻia no ka mālama ʻana i nā maʻi o nā maʻi cardiovascular. I ka makahiki 2004, ua paʻi ʻia nā hualoaʻa o ke aʻo ʻana ʻo ARMYDA - Atorvastatin no ka hōʻemi ʻana i ka hōʻino ʻana i ka hapa ʻana o ka moku ʻana i ka wā o Angioplasty. I ka poʻe nāna i lawe Liprimar 40 mg i kēlā me kēia lā ma mua o ka angioplasty coronary, ua ʻoki loa ka ʻeha ʻana ma mua o nā poʻe maʻi i loaʻa ʻole i statins. ʻO kekahi noiʻi hou, i kapa ʻia ʻo STATIN STEMI, i hōʻike ʻia ma ka atorvastatin hiki ke kuhikuhi ʻia i loko o nā kakalolo o 10 a 40 mg paha i kēlā me kēia lā ma mua o ka hoʻolilo ʻana no nā lā 7, ʻaʻohe ʻano ʻē aʻe.

I ka makahiki 2005, i paʻi ʻia nā hopena o ka noiʻi IDEAL - Hoʻomoe ʻana i loko o nā wahi hope ma o nā hua nui i loaʻa iā Aggressive Lipid-lowing. Ka mea i loko o ka manawa lōʻihi, atorvastatin i ke koena nui o 80 mg i kēlā me kēia lā ke kōkua i nā poʻe i hōʻeha i ka puʻuwai ʻokoʻa ʻole ma mua o simvastatin 20 mg i kēlā me kēia lā. ʻO 8888 nā mea maʻi i komo, a ʻo ka mea i ukali ʻia ma kahi o 5 mau makahiki. ʻAʻole i kuhikuhi ʻia ʻo Atorvastatin a me simvastatin i nā maʻi i ka manawa koke, akā he 21-23 mau mahina ma hope o ka hōʻeha ʻana o ka naʻau. I nā hola mua a me nā lā ma hope o ka hōʻeha ʻana o ka puʻuwai, ʻo ia nō ka loli o ka nui a me nā koina o Liprimar e hoʻomaikaʻi maikaʻi i ka prognosis ma mua o nā wai haʻahaʻa o ka atorvastatin a i ʻole nāwaliwali simvastatin.

ʻEha puki

Atorvastatin a me nā statins me ka lōʻihi ke hoʻolōʻihi i ka hopena o ka hōʻeha ʻana i nā maʻi me nā maʻi hypertension, maʻi maʻi coronary a me ka maʻi maʻi. I loko o kahi ʻōlelo o Ianuali 2004 kahi o ka European Journal of Medical Research, ua noi ʻia kahi ʻano noiʻi o kekahi mau noiʻi e pili ana i ka hana o nā statins no ka pale ʻana i ka hōʻeha keu. Wahi a ka lawe ʻana i nā papa liprimar e hōʻemi i ka hopena o ka hōʻeha ma ka 41%, a me ka mālama ʻana me simvastatin - e 34%. E lawe ʻia nā ʻōmala no ka pale ʻana i ka hōʻeha e nā poʻe e loaʻa i ka cholesterol maʻamau, akā aia kekahi mau mea ʻē aʻe, ʻoi aku ka nui o ka protein C-reactive.

E ʻike i pehea e kūpono ai i ka atorvastatin i ka pale ʻana i ke kūʻi hou ʻana, kahi hōʻike SPARCL, Stroke Prevention e Aggressive Reduction in Cholesterol Level, i mālama ʻia me nā maʻi 4371. ʻO nā mea maʻi i loaʻa i kahi hōʻeha ischemic i loko o nā 6 mau mahina i hala ua kau ʻia i ka atorvastatin (ka lāʻau lapaʻau mua ʻo Liprimar) ma 80 mg i kēlā me kēia lā, kahi keu o ka hana maʻamau. Aia kekahi pūʻulu koa o nā mea maʻi i lawe i kahi placebo ma mua o ka lāʻau maoli nō. Ua nānā ʻia nā mea maʻi a pau no 5 mau makahiki.

I waena o nā mea maʻi i mālama ʻia me ka atorvastatin, ʻo ka piʻi o ka wā o ka hōʻaiʻe i hōʻemi ʻia e 16% wale nō, i hoʻohālikelike ʻia me ka hui pletebo. Me he mea la ka hopena. Akā ua huli ʻo ia ka manaʻo o ka haʻahaʻa haʻahaʻa o nā mea komo i ka hoʻopaʻa ʻana. I ka hui atorvastatin, nui nā mea maʻi i lawe i kā lākou lāʻau lapaʻau i kuhikuhi ʻia. Ma kekahi ʻaoʻao, i ka hui placebo, nui nā mea maʻi i lawe i nā stins, i kuhikuhi ʻia e nā kauka i nā keʻena olakino ʻē aʻe. Ke hoʻololi nei i nā mākaʻi o ka kolamu ma ke koko, hiki iā ʻoe ke hoʻoholo inā lawe ka mea maʻi i nā statins a i ʻole. I waena o nā poʻe maʻi i hoʻomaʻamaʻa maoli ʻia me statins, ua emi ka nui o ke kūmaha i ka 31%. "

ʻO Renal hiki ʻole

ʻO Liprimar me nā lāʻau ʻē aʻe e lohi ana i ka hoʻomohala ʻana o ka hiki ʻole o ke pani i ka poʻe maʻi me ka maʻi mellitus. I ka lāʻo Malaki 2015, ua paʻi ka puke ʻo Lancet Diabetes & Endocrinology i nā hopena o ka PLANET aʻu e noi nei - kahi hoʻohālikelike o ka maikaʻi o ka atorvastatin a me ka rosuvastatin e pale aku ai i nā lolo i nā mea maʻi me ka maʻi diabetes type 1 a me ke ʻano type type 2. No kēia noiʻi ua 353 nā mea maʻi i mālama ʻia me nā mea maʻi ACE inhibitors a i ʻole blocker receptor-angiotensin-II. Kauka nā kauka iā lākou i hoʻokahi makahiki. Ka mea i lilo ʻoi loa ka rosuvastatin i lalo ka LDL kolamu hou a ʻoi aku ka ikaika, akā pale aku i kaʻeha ma mua o ka liprimar maikaʻi maikaʻi - ʻo ka atorvastatin maikaʻi.

I nā hihia liʻiliʻi, hiki i ka hopena ʻoi aku ke kūpaʻa o ka hopena o ka atorvastatin. Hoʻomaopopo kēia i ka wā i luku ʻia ai ka mauʻa skeletal. ʻO nā mea e hōʻino ʻole i nā aʻa ke komo i ke kahe wai. Loaʻa pinepine kēia ʻaoʻao. Hoʻonui ʻia ka pilikia no ka poʻe i hōʻike ʻia i ka maʻi maʻamau o ka maʻi a i ʻole ka hema ʻana o ka hormone thyroid. E ʻike i nā pilikia ma mua o ka loaʻa ʻana o nā pūpū maʻamau e hiki ai iā ʻoe ke lawe i kahi hōʻike koko ma ke ʻano kinase. ʻO Liprimar paha e hoʻoulu pinepine i ka pilikia o nā keiki ma mua o nā loina.

ʻAno maʻi type 2

ʻO Atorvastatin, e like me nā statins ʻē aʻe, e hoʻonui i ka nui o ka maʻi diabetes type 2 i ka poʻe i makemake i kēia maʻi. No nā mea i loaʻa i ka lolo, ʻo kēia lāʻau lapaʻau e hoʻoliʻiliʻi i ke kō koko a me ka glycated hemoglobin HbA1C. I ka manawa like, no ka poʻe i loaʻa ka maʻi kiʻekiʻe o ka maʻi cardiovascular, ʻoi aku ka nui o nā pōpoki o nā papa liprimar a i ʻole nā ​​statins ʻē aʻe i mua o ka hopena o ka maʻi maʻi a me nā hopena ʻē aʻe.

ʻO ka lawe ʻana i ka atorvastatin e hoʻonui i ka hanohano o ka maʻi maʻamau i ka poʻe ma luna o ka momona, ka mālama ʻana o ka momona i ka puni o ka ʻūhā, ke koko kiʻekiʻe, ke kolamu a me ka triglycerides i ke koko. I ka manawa hui, ua kapa ʻia kēia mau ʻōhua me ka metabolic syndrome. E aʻo i ka ʻatikala "Kāohi i ka puʻuwai hōʻeha a me ke koʻokoʻo" e ʻike ai pehea e hoʻomalu ai i ka metabolism maʻi kīnā ae pale iā ʻoe iho i ka maʻi diabetes. E hānai i nā manaʻo ʻōlelo i loko o ka ʻatikala. I kēia hihia, hoʻomau e lawe i Liprimar a i nā statins ʻē aʻe e hōʻemi i kou hopena cardiovascular. He mea nui loa ia i ke kāohi i ke kō koko koko no nā wahine i loaʻa i ka menopause. No ka mea ke lawe lākou i ka atorvastatin, hoʻonui lākou i ka maʻi o ka maʻi maʻi i ka nui loa.

Liprimar no ka maʻi maʻi: ka loio a me nā ʻaha

ʻOi aku ka kiʻekiʻe o ka puʻuwai cardiovascular maʻi, ʻoi aku ka nui o ka pono o ka mālama ʻana me ka atorvastatin a i ʻole nā ​​statins ʻē aʻe. ʻO nā maʻi maʻi maʻi āpau 2 ʻo ia ka poʻe i loaʻa ka kiʻekiʻe o ka hōʻeha o ka puʻuwai, ke kuʻi, a me nā pilikia ʻē aʻe. Lawe mai ʻo Liprimar iā lākou i nā pōmaikaʻi nui, ʻoiai inā hoʻonui iki i ke kō koko a me ka hemoglobin glycated. No ka laʻana, kahi noiʻi CARDS (ʻO ka Kolaborative Atorvastatin Diabetes Study) i hōʻike ʻia i ka atorvastatin ma kahi waʻa o 10 mg wale nō i kēlā me kēia lā e hōʻemi ana i ka hopena cardiovascular ma ka maʻi maʻi ma kahi o 37%. ʻOi aku ka maikaʻi o nā maʻi maʻi diabetes i ka lawe ʻana i nā statins ma mua o nā makahiki like ʻole me ke kō koko koko maʻamau. A mai makaʻu i nā kiʻekiʻe kiʻekiʻe ma atorvastatin. Mai kaupalena iā ʻoe iho e lawe i 10 mg i kēlā me kēia lā inā ʻaʻole lawa ka nui o kēia maʻa.

E heluhelu i ka kikoʻī kikoʻī "Statins and Diabetes." E aʻo pehea e hoʻomaʻamaʻa i kou koko koko, ke kō C-reactive, a me nā mea koʻikoʻi cardiovascular ʻē aʻe. Hiki ke mālama maʻalahi ʻia ka maʻi maʻamau 2 me ka ʻole o ka ʻai "pololi", nā pā maikaʻi ʻole a me nā inikua insulin. Hūnā nā kauka i kēia ʻike no ka mea ʻole e nalowale i nā mea kūʻai aku.

ʻO ka maʻi metabolic

ʻO ka metabolic syndrome kahi paʻakikī o nā hōʻailona o ka metabolism, ka hopena i hoʻemi ʻia i ka insulin. Loaʻa i nā waihona momona o ka ʻōpū (ka ʻōpū o ka ʻōpū), ke kiʻekiʻe o ka maʻi, ka hopena o ka hoʻāʻo ʻana no ka cholesterol a me ka triglycerides. Māhuahua ka lāʻau Metabolic i ka hōʻeha o ka pilikia cardiovascular ma ka 44%. No laila, nā mea maʻi e hāʻawi ʻia i kēia maʻi, kuhikuhi pinepine nā kauka i ka atorvastatin a i ʻole nā ​​statins ʻē aʻe. Wahi a ka noiʻi TNT (Hoʻomake ʻana i ka New Targets), i nā mea maʻi me ka metabolic syndrome, atorvastatin (ka lāʻau lapaʻau maoli ʻo Liprimar) i hōʻemi ʻia ka hopena o ka hōʻeha ʻana o ka puʻuwai, hōʻeha, ka hoʻokūkū a me nā hoʻokele by coronary e ka 29%.

Kōkua nā statins i nā maʻi me ka metabolic syndrome, no ka mea e hoʻohaʻahaʻa lākou i ka "bad" kolesterol i ke koko, a ma muli o nā hopena pleiotropic, i hōʻike ʻia ma luna. Eia naʻe, ʻo ka hana nui (kāohi) o ka metabolic syndrome ʻo ia ka hoʻololi i ke ola olakino, ʻaʻole ka lāʻau lapaʻau. Atorvastatin, nā mīkini paʻi, a me nā lāʻau ʻē aʻe wale nō e hoʻohui wale nei, akā ʻaʻole hiki ke hoʻololi i kahi ʻai olakino a me ka hoʻonaʻauao kino ʻokoʻa. E heluhelu ma aneʻi pehea e lawe ai i ka metabolic syndrome me ka ʻole o ka 'pōloli' a me ka hana paʻakikī. E aʻo pehea e hoʻohololei ai i ke koko ma o ka hāʻawi ʻana i nā lāʻau pōʻino.

Lapaʻau lāʻau

ʻO ka papa hana ikaika o ka lāʻau, atorvastatin, he mea pale i kālai ʻia o ka ʻōnaehana kī nui i kuleana no ka hoʻololi ʻana o HMG-CoA reductase i mevalonate (kahi hana mua i ka sterols). Kōkua ia i ka hoʻemi ʻana i ka cholesterol ma ke koko ma o ka hoʻohaʻahaʻa ʻana i kona synt synt i loko o ka ate a me ka hoʻonui ʻana i ka nui o nā receptors LDL ma ka lepa o nā mea i kuleana no ka catabolism o nā lipoproteins haʻahaʻa haʻahaʻa.

I nā poʻe maʻi e hōʻeha nei i ka hoʻoilina ʻōpiopio, ka hypercholesterolemia familial (nā ʻōhua a me ka heterozygous ʻano), a me nā ʻano like ʻole o ka dyslipidemia.

Ke hoʻohana nei iā Liprimar, aia ka emi i ka nui o ka maʻi nonfatal a me ka hoʻoulu ʻana i ka naʻau, nā maʻi hōʻiliʻili o ka maʻi momona, a me ka pono o ka myocardial revascularization.

ʻO ka hoʻomaʻamaʻa maikaʻi ʻana i ka pae o ka kolamu, ʻo B. triglycerides apolipoprotein a me X-LDL, ʻaʻole i hoʻopōʻino ka lāʻau i ka ulu a me ka puberty o nā keiki a me nā wā'ōpiopio a ʻaʻole hōʻole i ka lōʻihi o ke kauā ʻana o ka hakakā ma nā kaikamahine (nā hopena hoʻokolohua lapaʻau).

Lapaʻau lāʻau

ʻO Liprimar, i ka wā i lawe ʻia ma ka waha, ua hoʻopili ʻia e ka ʻūhā, e hōʻea i nā pihi plasma kiʻekiʻe ma hope o 2 mau hola. Hoʻohālikelike ʻia ka plasma o ka lāʻau i ka hopena i lawe ʻia (ma ka waena o 10-20-40-80 mg). ʻO ka bioavailability piha o nā papa, i hoʻohālikelike ʻia me ka nā hoʻonā, ʻo 95-99%, ka loaʻa ʻana o ka systemic he 30% (pili kēia hōʻailona me ka presystemic clearance o atorvastatin i ka papa gastrointestinal a me ka hopena o kāna kaila mua ma o ka ʻōpū). Ke lawe nei i ka lāʻau lapaʻau me ka meaʻai, he liʻiliʻi iki i ka bioavailability.

Ke kamaʻilio pū ʻana me nā protein plasma - 98%. Ma ke kaʻina o ka maʻi hepatic metabolism, ke ulu nei ke ʻano o nā mea kanu pharmacologically (e pili ana i 70% o ka hopena therapeutic o ka lāʻau ma muli o kona hoʻopuni metabolites).

Hoʻopili nui ʻia ʻo Atorvastatin e ka ʻōpū ma ka ʻāpana. Me nā keiki liʻiliʻi - 2% wale nō. Eia naʻe, ʻaʻole i ʻike ʻia ka recirculation enterohepatic nui. ʻO ka hapalua ola o ka pakanui kaha 14 mau hola. ʻO ka lōʻihi o ka hopena hopena (ma muli o nā metabolites e hele i loko o ke koko) he 20-30 mau hola.

I nā maʻi o nā makahiki holomua, i ka hoʻohālikelike ʻana me nā wahine a me nā kāne, ua ʻike ʻia kahi hoʻonui ʻana o ka plasma o ka atorvastatin.

Hoʻopilikia ʻole nā ​​maʻi hanana a pau i ka pili ʻana i ka pharmacokinetics o ka lāʻau. I ka hihia o ka hana heʻumi kūpono i ka plasma koko, i ke kiʻekiʻe o ka hana ʻole i hoʻololi ʻole ʻia e hoʻonui.

ʻO nā ʻōlelo aʻo Liprimar (Atorvastatin) no ka hoʻohana

mea waiwai: atorvastatin, 1 papa he mau calcium atorvastatin, he mea e kū like ai i ka 10 mg a 20 mg, a i ʻole 40 mg, a i ʻole 80 mg o ka atorvastatin,
nā mea hoʻowalewale: calcium carbonate, microcrystalline cellulose lactose monohidrat, sodium croscarmellose, polysorbate 80 hydroxypropyl cellulose, magnesium stearate film coating (hydroxypropyl methyl cellulose, polyethylene glycol 8000, titanium dioxide (E 171), talc) emulsion simethic waikama).

ʻO nā waiwai Pharmacological

ʻO Liprimar kahi lāʻau lapaʻau lipid-hoʻemi haʻahaʻa. ʻO Atorvastatin kahi hoʻomehana o 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.Ua hoʻohālikelike kēia enzyme i ka hoʻololi ʻana o HMG-CoA i mevalonate - kahi wana mua o ka biosynthesis o ka kolamu e kaupalena ana i ka helu o kona kūkulu.

ʻO Liprimar kahi mea koho paʻa koho no HMG-CoA reductase, he enzyme e hoʻoholo ana i ka hoʻololi ʻana o ka 3-hydroxy-3-methylglutaryl coenzyme A i ka mevalonate, kahi mea mua no ka sterols, me ka kolamu. Kālā ʻo Cholesterol a me nā triglycerides i ke kahe koko e hui pū me nā lipoproteins. Ua hoʻokaʻawale ʻia kēia mau paʻakikī e ka ultracentrifugation i loko o nā māhele o ka HDL (lipoproteins density kiʻekiʻe), HDL (lipoproteins density interdate.), LDL (lipoproteins haʻahaʻa haʻahaʻa) a me VLDL (lipoproteins haʻahaʻa haʻahaʻa haʻahaʻa). Hoʻokomo ʻia ʻo Triglycerides (TG) a me ka cholesterol i ka ate ma ka VLDL a hoʻokuʻu i loko o ke kaila koko no ka lawe ʻana i nā ʻāpana peripheral. Hoʻokumu ʻia ka LDL e VLDL a kākuhi ʻia e ka pilina me nā mea hoʻokomo LDL kiʻekiʻe. Hōʻike nā haʻawina haukapila a me nā pathological i nā kiʻekiʻe kiʻekiʻe o ka kolamu (OX), LDL cholesterol (LDL-C) a me apolipoprotein B (apo B) i loko o ke koko koko a kōkua i ka hoʻomohala ʻana i ka atherosclerosis i loko o nā kānaka a he mau pilikia nā mea e hoʻomohala ai i nā maʻi cardiovascular, aʻo ʻOiai ke kiʻekiʻe o ka pae kiʻekiʻe o ka HDL cholesterol e pili ana i ka hoʻemi ʻana o ka hopena o ka maʻi cardiovascular.

I nā hoʻohālike holoholona hoʻokolohua, hoʻoemi ai ka lyprimar i ka plasma cholesterol a me ka pae lipoprotein ma ke kaohi ʻana i ka hoʻōla ʻana o ka HMG-CoA i ka palaleka a me ka hoʻohuihua o ka kolamu a me ka hoʻonui ʻana i ka nui o nā mea hoʻokipa LDL hepatic ma ka pūlima e hoʻomaikaʻi ai i ka hoʻopili ʻana a me ka catabolism o LDL a me ka liprimar e hōʻemi ana i ka hoʻolaʻa LDL a me ka nui o kēia mau helu ʻōpio. Hōʻemi ka liprimar i ka cholesterol LDL i kekahi mau mea maʻi me ka hypercholesterolemia homozygous homozygous, ʻo ia hoʻi, nā hui o nā poʻe e ʻike iki ana i ka maʻi me nā lāʻau lapaʻau hypolipidemic.

Ua hōʻike ʻia nā haʻawina hoʻokolohua nui i ke kiʻekiʻe o ka kolamu, LDL kolamu a me apo B (kahi membrane complex no LDL cholesterol) hoʻonāukiuki i ka hoʻomohala ʻana o ka atherosclerosis. Pēlā nō, hoʻohaʻahaʻa i nā pae o HDL cholesterol (a me kāna ʻoihana hoʻonaninani - a me A) pili i ka hoʻomohala ʻana o ka atherosclerosis. Ua ʻike ʻia nā haʻawina ʻo Epidemiological e like me ka morbidity cardiovascular a me ka make ma ka hoʻohālikelike i ka pae o ka nui o ka kolamu a me ka LDL cholesterol a me ka hewa ʻole i ka pae o HDL cholesterol.

ʻO ka liprimar ka mea haʻahaʻa o ka cholesterol, LDL cholesterol a me apo B i nā mea maʻi me ka hypercholesterolemia homozygous a me ka heterozygous, kahi ʻohana ʻole o ka hypercholesterolemia a me ka dyslipidemia i hui ʻia. Hoʻololi ʻo Liprimar i ka VLDL a me ka cholesterol cholesterol, a hoʻopuka pū kekahi i ka hoʻonui ʻole ʻana i ka koleka HDL a me ka ʻApolipoprotein A-1. ʻO ka liprimar ka mea haʻahaʻa o ka cholesterol, LDL cholesterol, VLDL cholesterol, apo B, triglycerides a me HDL cholesterol, a hoʻonui pū kekahi HDL cholesterol i nā mea maʻi me ka hypertriglyceridemia hoʻokaʻawale. Hōʻemi ka liprimar i nā testosterone-hoʻohaʻahaʻa i nā steroid i nā maʻi me ka dysbetalipoproteinemia.

E like me LDL, lipoproteins i hoʻonui ʻia i ka cholesterol a me ka triglycerides, e komo pū ana me VLDL, STD a me nā koena, hiki ke hāʻawi pū i ka hoʻomohala ʻana i ka atherosclerosis. Hoʻomaka pinepine ka plasma triglycerides i kahi triad me nā haʻahaʻa haʻahaʻa o ka kolamu HDL a me nā kiʻi LDL liʻiliʻi, a me ka hui pū me nā mea kūlohelohe metabolabous non-lipid no ka maʻi ʻeha coronary. ʻAʻole nō i hōʻike mau ʻia i ka pae nui o ka triglycerides plasma e like me kahi mea kūʻokoʻa kūʻokoʻa no ka hoʻomohala ʻana i ka maʻi naʻau coronary. Eia kekahi, ʻo kahi hopena kūʻokoʻa i ka hoʻonui ʻana i ke kiʻekiʻe o ka HDL a i ʻole ka hoʻohaʻahaʻa i ka triglycerides i ka hopena o ka coronary a me ka morbidity coronary a me ka make ma mua.

ʻO Liprimar, e like me kekahi o kāna mau metabolites, he pharmacologically ikaika i ka poʻe. ʻO ka pūnaewele nui o ka hana a atorvastatin ka mea leʻawa, e hana ana i nā kūlana koʻikoʻi ma ke kāpili ʻana o ka cholesterol a me ka hoʻomaʻemaʻe ʻana o LDL. ʻO ka hopena o ka lāʻau lapaʻau, ʻaʻole i hoʻohālikelike i ka ʻōnaehana o ka loina i ka lāʻau, ua ʻoi aku ka maikaʻi i ka hoʻokaʻawale i ka kolamu LDL. ʻO ka koho maʻi pākahi kanaka pono e lawe ʻia ma muli o ka pane therapeutic (ʻike i ka ʻāpana "Dosage a me ka Management").

Kapehu. Hoʻokomo koke ʻia ka liprimar ma hope o ka lawelawe waha a ua hōʻea hoʻi kona kiʻekiʻe plasma i loko o 1-2 mau hola. Ka hoʻonui ʻia o ke kīhāpai i ka hapa o ka lymprim o ka lāʻau. ʻO ka bioavailability o atorvastatin (ka lāʻau lapaʻau makua) ma kahi o 14%, a me ka bioavailability o ka ʻōnaehana o ka hana pale ʻana e kūʻē i ka HMG-CoA reductase ma kahi o 30%. Loaʻa ka haʻahaʻa sistemino haʻahaʻa o ka lāʻau me ka hoʻomaʻemaʻe mua o nā ʻōnaehana i ka membous mucous o ka gastrointestinal tract a me / a i ʻole pre-system biotransformation i loko o ka puʻuwai. ʻOiai ka ʻai ʻana o ka meaʻai i ka helu a me ka nui o ka inu ʻana o ka lāʻau i ka 25% a me 9%, kahi, e pili ana i ka C max a me AUC, ka hoʻohaʻahaʻa ʻana i ka kolamu LDL e like ʻole me ka lawe ʻia a lypimar me ka meaʻai a ʻokoʻa paha. Ke hoʻohana nei i ka atorvastatin i ke ahiahi, ʻoi aku ka ʻike ma ka pili koko (ma kahi o 30% no C max a me AUC) ma mua o ke kakahiaka. Eia nō naʻe, ʻo ka emi ʻana o ka kolamu LDL e like me ka manawa o ka lawe ʻana i ka lāʻau (ʻike i ka ʻāpana "Dosage a me ka Administration").

Kahele. ʻO ka nui nui o ka laha ʻana i ka lāʻau lyprimar ma kahi o 381 lita. ʻOi aku ma mua o 98% o ka lāʻau lapaʻau e hoʻopili i nā protein plasma. ʻO ka ratio o ke kahe o ke koko / plasma e like me 0.25, e hōʻike ana i ka ke komo ʻana o ka lāʻau i loko o nā ʻāpana koko ʻulaʻula. Ma muli o nā mea ʻike i nā kiʻī, ua manaʻo ʻia ua hiki i ka lypimar ke komo i loko o ka waiū umauma (e nānā i nā Māhele "Contraindications", "E hoʻohana i ka wā o ka wā hāpai a me ka luhilahi a me nā" ʻano o nā hoʻohana ").

Hāpai. Hoʻololi nui ʻia ka liprimar i nā derivatives o ortho a para para-hydroxylated a me nā ʻano huahana like ʻole o ka beta oxidation. I loko o nā haʻawina vitro, ʻo ka paleʻana o ka HMG-CoA reductase ortho a me ka pālahalohilohila pālua e pāhāhā me nā māhina. Ma kahi o 70% o ka hana pale kaawena e kūʻē i ka HMG-CoA reductase e pili ana me ka metabolites hoʻoikaika. I loko o nā haʻawina vitro hōʻike i ke koʻikoʻi o ka hana o ka metabolism o ka lyprimar cytochrome P450 3A4, kahi e kū like me ka nui o ka ʻike ʻana o ka lālani lypimar i loko o ke koko koko o ka poʻe ma hope o ka hoʻohana like ʻana me ka erythromycin, kahi mea i ʻike ʻia e kēia ʻenepine (e ʻike i ka ʻāpana "Hoʻohui me nā lāʻau lapaʻau ʻē aʻe").

ʻĀina. Hoʻokomo ʻia ʻo Liprimar a me kāna metabolites me ka bile ma hope o ka hepatic a / a i ʻole he metabolism extrahepatic naʻe, naʻe naʻe kēia lāʻau lapaʻau, ʻaʻole ʻike ʻia ka recirculation gastrohepatic. ʻO ka hapalua o ka lypimar mai plasma koko o ke kanaka ma kahi o 14 mau hola, akā ʻo ka manawa o ka hoʻohaʻahaʻa i ka hana inhibitory kūʻē i ka hoʻolaʻa ʻana o HMG-CoA mai 20 a 30 mau hola ma o ka hāʻawiʻana o nā metabolites ikaika. Ma hope o ka lawe ʻana i ka lāʻau lapaʻau me ka urine, hōʻemi ma mua o 2% o ka nui a excreted.

ʻO nā maʻi maʻi. ʻO ke kiʻekiʻe o ka plasma o ka lyprimar ke kiʻekiʻe (ma kahi o 40% no C max a me 30% no AUC) i nā maʻi maʻi olakino (ma mua o 65 mau makahiki) ma ka wā ʻōpio. Hōʻike ka hōʻike o ka haukapila i kahi kiʻekiʻe o ka hoʻemi ʻana i ka LDL i ka wā e hoʻohana ai i kekahi lāʻau o ka lāʻau no nā mea maʻi kahiko e hoʻohālikelike ʻia me nā poʻe ʻōpio (e nānā i nā ʻāpana "Features of use")

E na keiki. ʻAʻohe data pharmacokinetic no kahi pūʻulu o nā maʻi maʻi pediatric.

Paul ʻO ka ʻike ʻana o ka lymprim lapaʻau i loko o ke kaila koko o nā wahine he ʻokoʻa i ka neʻe i loko o ke koko koko o ka u (ma kahi o 20% kiʻekiʻe no C max a me 10% haʻahaʻa no AUC). Eia nō naʻe, ʻaʻohe iki o ka ʻokoʻa i loko o ka hōʻemi ʻana i ka LDL cholesterol i ka wā e hoʻohana ai i ka lālani lypimar i nā kāne a me nā wahine.

Hola paʻa kino hana. ʻAʻole hoʻopilikia ka maʻi ʻeha i ka nānā ʻana o ka lymprim lapaʻau i loko o ke kaila koko a i ʻole ka hāʻule ʻana o ka kolamu LDL, a, no laila, ʻaʻole koi ʻia ka hoʻoponopono ʻana o nā maʻi no nā maʻi me ka hana ʻole a pau.

Hemodialysis ʻOiai ʻaʻole i hana ʻia nā haʻawina i loko o nā mea maʻi me ka maʻi hope o ka maʻi hope, a manaʻoʻiʻo ʻo ka hemodialysis ʻaʻole e hoʻonui nui i ka maʻemaʻe o ka liprimar, no ka mea, ua paʻa ka lāʻau lapaʻau i nā protein plasma.

ʻO ka hana hema ʻole. Hoʻomua ka ʻike o ka lymprim lāʻau i loko o ke kaila koko me ka nui o nā mea maʻi me ka maʻi ʻalopona kūloko maʻi. ʻO nā waiwai o C max a me AUC he 4 mau manawa kiʻekiʻe i nā maʻi me nā maʻi A mahele e like me ke kāʻei keiki-Pugh. I ka poʻe maʻi me ka maʻi pēpē keiki-Pugh, nā māka o C max a me AUC e hoʻonui i ka 16-pilipoi a me 11-mau pākeke, ia manawa (e nānā i ka ʻāpana "Contraindications").

ʻO ka hopena o nā lāʻau lapaʻau like i ka manawa ma ka pharmacokinetics o atorvastatin

Liprimar no ka elemakule

ʻO Liprimar, e like me nā statins ʻē aʻe, i ʻōlelo ʻia no ka poʻe kahiko e loaʻa pū i ka maʻi puʻuwai coronary. ʻO kēia lāʻau lapaʻau e hōʻemi i ka hopena o ka hoʻoulu ʻana o ka puʻuwai, hōʻeha, ka pono no ka hoʻokele a coronary artery bypass grafting. ʻ recommendlelo aku nā ʻatikala ma nā nūpepa olakino ʻē aʻe i atorvastatin e kuhikuhi i ka poʻe ʻelemakule ma nā māmā a me nā kiʻekiʻe kiʻekiʻe, ʻaʻole hoʻi ma ka haʻahaʻa. Pili kēia palapala i nā mea maʻi 65-78 mau makahiki he nui ka maʻi cardiovascular - me ka maʻi o ka angina pectoris, atherosclerosis o nā hana haʻahaʻa o ka mea i loaʻa ka puʻuwai puʻuwai, hōʻeha a me nā ʻoihana paha e hoʻihoʻi i ke kahe koko i loko o nā ʻalā. Inā atorvastatin 10 mg i kēlā me kēia lā ʻaʻole e kōkua nui, a laila pono ʻoe e hoʻonui i ka dosage. ʻO nā hopena ʻaoʻao ka liʻiliʻi ma mua o ka make a i ʻole ke kīnā ma muli o ka hōʻeha ʻana o ka naʻau.

Ma 2009, ua paʻi ka nūpepa Clinical Cardiology i nā hopena o kahi hōʻike ma laila ua komo ka 2442 nā mea maʻi maʻi me ka maʻi ʻeha coronary. ʻO ka hapalua o lākou i kuhikuhi i ka liprimar i nā kiʻekiʻe kiʻekiʻe, a he 80 mg i ka lā, a ua hāʻawi ʻia ka lua o nā atorvastatin a me nā statins ʻē aʻe i nā pehu haʻahaʻa a me nā palena. ʻImi nā kauka i nā mea i komo i ka aʻo ʻana no 4.5 mau makahiki. I ka poʻe maʻi e lawe ana i nā koina kiʻekiʻe o atorvastatin, hoʻemi ʻia ka pilikia cardiovascular e ka 27% i hoʻohālikelike ʻia me ka hui lua. ʻO nā hopena ʻaoʻao mai ka lawe ʻana i nā statins e nānā pinepine ʻia i nā poʻe maʻi ma mua o nā ʻōpio. Akā ʻaʻole i kūlike loa ko lākou laha ma nā hui ʻelua.

Hoʻolaha ʻia ʻo Cholesterol ma nā keiki

Ma ʻIkeʻakeʻo, ʻo ka lāʻau lapaʻau ka mea kūlohelohe mua atorvastatin i kuhikuhi ʻia no nā poʻe ʻōpio i maʻi ʻia me ka maʻi lahilahi e loaʻa ʻole - heterozygous familial hypercholesterolemia. Hiki ke mālama ʻia me kēia mea hana, e like me nā statins ʻē aʻe, e hoʻomaka ana mai ka makahiki 10 mau makahiki. Hiki i nā kaikamahine ke lawe i nā statins i hoʻokahi makahiki wale nō ma hope o ko lākou hānau ʻana.

ʻO Liprimar i ka mālama ʻana i ka hypercholesterolemia familial e hoʻopiʻi i nā hopena ʻeha i kahi pinepine ma mua o ka pletebo. ʻAʻohe ʻikepili i ka hopena o kēia lāʻau lapaʻau no nā keiki ma lalo o 10 mau makahiki o ka makahiki. I nā hoʻokolohua lapaʻau, ua hoʻonoho ʻia ka atorvastatin i nā keiki a me nā ʻōpio i nā nui o nā mea ʻaʻole i kiʻekiʻe aʻe ma mua o 20 mg i kēlā me kēia lā. No laila, ʻaʻohe mea e pili ana i ke ʻano o ka nui aʻe o ka hana. I nā ʻāina ʻōlelo Lūkia, ʻo ka makahiki o 18 he contraindication mana i ka koho ʻana o ka atorvastatin.

Ua ho'ākāka ka ʻatikala i nā mea a pau e pono ai i nā poʻe maʻi e ʻike e pili ana i ka hoʻohana ʻana o atorvastatin. ʻO keʻano kūikawā, ua wehewehe pono i nā hopena ʻaoʻao - he nīnau e hoʻopilikia ai i nā mea āpau. E ʻike pū kekahi kauka i nā mea pono e pili ana iā lākou iho. Hoʻoikaika ʻo Atorvastatin i ka kolesterol "hewa" i loko o ke koko ma mua o nā statins mua ma mua - lovastatin a me simvastatin. ʻAʻole ia e hoʻolale wale i ka hoʻomohala ʻana o ka atherosclerosis, akā ke hōʻemi ʻana i ka mānoanoa o nā kīwaha atherosclerotic. ʻAʻole pili ka lāʻau lapaʻau i nā hapalua koloka, i ka mea i kū ʻia ma nā paia o nā kīhaka. ʻO Liprimar - ka lāʻau lapaʻau mua o ka atorvastatin, ka mea i manaʻo ʻia ʻo ke ʻano maikaʻi loa. Inā loaʻa nā kālā kālā, a laila e lawe. Inā makemake ʻoe e mālama i ke kālā, e kamaʻilio i kāu kauka e pili ana i ka hoʻololi ʻana i nā papa atorvastatin mai nā mea hana ʻē aʻe.

ʻO Rosuvastatin kahi lāʻau hou loa ma mua ma atorvastatin. I kēia manawa i loko o ka lāʻau kūʻai lāʻau i waena o nā statins aia kekahi hoʻokūkū nui ma waena o kēia mau lāʻau. ʻAʻole i manaʻo ʻia ʻo Atorvastatin e hoʻonui i ka hopena o ka maʻi maʻi e like me ka rosuvastatin. ʻO Atorvastatin ka mea i makemake ai no nā mea maʻi me ka nele puʻuwai. Mālama ka lāʻau lapaʻau mua iā Liprimar i nā ʻeha i loko o nā mea maʻi me ka maʻi type a me ka type 2 like iʻoi aku ma mua o rosuvastatin. Akā ʻaʻole ia i ʻike inā kōkua ʻia nā papa hoʻonaninani atorvastatin i nā maʻi maʻi. ʻO ka koho o kahi lāʻau lapaʻau pono e pono e hana e ke kauka hele mai. Mai hoʻolaʻa pilikino.

Me ka mālama pono

I ka poʻe maʻi e hōʻino maikaʻi ʻana i ka waiʻona, i nā mea maʻi me ka mōʻaukala o nā maʻi ate.

I ka poʻe maʻi me nā mea e pili ana i ka rhabdomyolysis (hana i ʻole ka hana, ka maʻi hypomyroidism, ka puʻuwai ma ka mana ʻōiwi i ka mōʻaukala a me ka mōʻaukala hanana ʻana, ka hopena ʻona o ka HMG-CoA reductase inhibitors (statins) a e hoʻopili ana i ka ʻōpū mākia, kahi mōʻaukala o ka maʻi pāpaʻi a / a i nā mea maʻi e inu i nā wai ʻona nui, ma luna o 70 mau makahiki he mau makahiki, nā kūlana e manaʻo ʻia ai nā manaʻo o ka atorvastatin plasma (e.g., kamaʻilio me nā lāʻau ʻē aʻe. keila)).

Heterozygous familial hypercholesterolemia

ʻO ka maʻa mua he 10 mg i kēlā me kēia lā. Pono ke koho pono ʻia i ka pākuhi a loiloi i ka pilina o ke ana i kēlā me kēia mau hebedoma 4 mau me kahi hoʻonui e hoʻonui i ka 40 mg i kēlā me kēia lā. A laila, hiki ke hoʻonui ʻia i kēia helu i ka nui o 80 mg pākahi i kēlā me kēia lā, a i ʻole he mea hiki ke hoʻohui i nā sequestrants o nā waikawa bile me ka hoʻohana ʻana i atorvastatin ma kahi kikoʻī o 40 mg pākahi.

Kāohi pilikia Cardiovascular

I nā haʻawina o ka pale mua, ʻo ka nui o ka atorvastatin he 10 mg i kēlā me kēia lā. Pono paha kahi hoʻonui hoʻonui e hoʻokō ai i nā waiwai LDL-C e kūlike me nā alakaʻi.

Hoʻohana ma nā keiki mai 10 a 18 paha mau makahiki me ka hypercholesterolemia ʻohana heterozygous

ʻO ka papa ʻōlelo hoʻomaka ʻia he 10 mg hoʻokahi i ka lā. Hiki ke hoʻonui ʻia ka nui i ka 20 mg i kēlā me kēia lā, e pili ana i ka hopena lapaʻau. ʻO ka ʻike me kahi mahele o ka 20 mg (e pili ana i ka nui o ka 0.5 mg / kg) ua palena.

Pono ka dosis o ka lāʻau ke titrated ma muli o ke kumu o ka lipid-hoʻohaʻahaʻa i ka ʻoihana. Pono e hoʻoponopono ʻia nā pila ma nā wā 1 o 4 mau hola i hoʻokahi a keu paha.

Hoʻohana me ka hui pū me nā lāʻau ʻē aʻe

Inā pono, e hoʻohana ʻia ka hoʻohana ʻana me ka cyclosporine, telaprevir a i ʻole hui i nā tipranavir / ritonavir, ʻaʻole pono ka nui o ka hopena o Liprimar eʻoi aku ma mua o 10 mg / lā.

E pono e hoʻohana ʻia me ka papa liʻiliʻi a me ka hopena o ka atorvastatin e hoʻokaʻawale ʻia a ʻo ia nō ka hoʻohana ʻana me ka inhibitor HIV protease, hepatitis C protease inhibitors (boceprevir), clarithromycin a me itraconazole.

Hoʻohana i ka wā hāpai a me ka lactation

ʻO controsed a Liprimar i ka wā hāpai.

Pono nā wahine o nā makahiki hānau hānau i nā ala kūpono o ka contraception i ka wā mālama. Hoʻopili ʻia ka hoʻohana ʻana o Liprimar i nā wahine o ka wā hānau keiki ʻaʻole ia e hoʻohana i nā ʻano kūpono o ke kūpaʻa.

Ua nānā ʻia nā hihia keu o ka kongenital anomalies ma hope o ka hoʻolaha ʻana i ka maʻi fetus i loko o ka ʻōpū ma hope o ka HMG-CoA reductase inhibitors (statins). Ua hōʻike nā noiʻi holoholona i nā hopena laʻala ma ka hana hānau. ʻO contrected Liprimar i ka wā lactation. ʻAʻole i ʻike ʻia inā excreted i ka atorvastatin i loko o ka waiū umauma. Inā pono e kuhikuhi i ka lāʻau lapaʻau i ka wā lactation, pono e ʻoki ʻia ka ʻōpū o ka pale ʻana i ka hopena o nā hanana ʻino i nā pēpē.

Pilikia ka pehu

E like me ka hoʻohana ʻana o nā lāʻau lapaʻau lipid-haʻahaʻa o kēia papa, me ka hoʻohana ʻana i ka lāʻau Liprimar, he hoʻonui haʻahaʻa (ʻoi aku ʻo 3 mau manawa i hoʻohālikelike ʻia me VGN) o ka hana o nā transaminases hepatic AST a me ALT. ʻO ka hoʻonui pinepine mau i ka hana serum o nā transaminases hepatic (ʻoi aku ma mua o 3 mau manawa i hoʻohālikelike ʻia me VGN) i nānā ʻia ma 0.7% o nā mea maʻi e loaʻa iā Liprimar. ʻO ka pinepine o nā loli i ka wā e hoʻohana ai i ka lāʻau lapaʻau ma nā inika o 10 mg, 20 mg, 40 mg a me 80 mg o 0.2%, 0.2%, 0.6% a me 2.3%, kēlā me kēia. I ka piʻi pinepine ʻana o ka hana hepatic transaminase maʻamau ʻaʻole i mālama ʻia e ka jaundice a i ʻole nā ​​hōʻike olakino ʻē aʻe. Me ka hoʻohaʻahaʻa ʻana i ka wai o Liprimar, ka wā ʻole a i ʻole piha i ka hōʻino ʻana i ka lāʻau, hoʻihoʻi ka hana o nā transaminases hepatic i kona pae mua. Hoʻomau ka hapa nui o nā poʻe maʻi e lawe i ka Liprimar i kahi emi iki me ka ʻole o kekahi hopena maʻi.

Ma mua o ka hoʻomaka, 6 mau hebedoma a me 12 mau pule ma hope o ka hoʻomaka ʻana o ka lāʻau lapaʻau a ma hope o ka hoʻonui ʻana i ka nui o ka nui, pono ia e nānā i nā ʻōnaehana hana pili. E nānā pū ʻia ka hana naʻau inā ʻike ʻia nā hōʻailona koʻikoʻi o ka hōʻeha o ka puʻuwai. I ka nui o ka hoʻonui ʻana i nā hana o ka transaminases hepatic, pono e nānā ʻia kā lākou hana a hiki i ka hoʻonui ʻia. Inā hoʻonui ka hoʻonui i ka hana o AST a i kahi ALT ma mua o 3 mau manawa i hoʻohālikelike ʻia me VGN e hoʻomau nei, e pono ana e hōʻemi i ka hopena a i ʻole ke kahuli ʻana iā Liprimar.

Pono e hoʻohana ʻia ka liprimar me ka makaʻala i nā mea maʻi e hoʻopau i nā nui o ka waiʻona a me / a i ʻole kahi moʻolelo o ka maʻi o ka ate. ʻO ka maʻi maʻi o ka ate a i ʻole mau loa ka hana o nā transaminases hepatic o ke kaila o ka puna kuʻuna o kahi kūmole he contraindication i ka hoʻohana ʻana o Liprimar.

Hoʻopau i nā io uaua o ka pōkole

Ua hoʻomaopopo ʻia ʻo Myalgia i nā maʻi e loaʻa ana iā Liprimar. Pono e noʻonoʻo ʻia i ka maʻi myopathy i loko o nā mea maʻi me ka hoʻolule i ka myalgia, ʻehaʻeha nā palupalu a i ʻole nāwaliwali a me / a me ke ʻano nui o ka hana KFK (ʻoi aku ma mua o 10 mau manawa i hoʻohālikelike ʻia me VGN). Pono e hoʻoneʻe ʻia ka liprimar e hoʻonui ʻia i kahi hana CPK, ma ke alo o ka myopathy i hoʻopaʻa ʻia a i ʻole. ʻO ka loaʻa o ka myopathy i ka wā e mālama ʻia me nā lāʻau lapaʻau hou o kēia papa me ka hoʻohana pinepine ʻana i nā mea paʻa ikaika o ka isoenzyme CYP3A (no ka laʻana, ka cyclosporine, telithromycin, clarithromycin, delavirdine, styripentol, ketoconazole, voriconazole, itraconazole, posaconazolein, ravira darunavir), gemfibrozil a i ʻole nā ​​fibrates, boceprevir, erythromycin, acid acidotinic i nā lipid e hoʻohaʻahaʻa i ka wai (ʻoi aku ma mua o 1 g / lā), ezetimibe, nā mea āpau azole antifungal, colchicine, telaprevir, boceprevir, a i ʻole kekahi hui o tipranavir / ritonavir. ʻOi aku ka nui o kēia mau lāʻau i ka CYP3A4 isoenzyme metabolism a me / a i ʻole lawe i nā mea i lawe i ka lāʻau. Ua ʻike ʻia ka cyenchrome CYP3A4 isoenzyme ka mahele nui isoenzyme i komo i ka biotransformation o atorvastatin. Kahi i ka Liprimar i hui pū me nā fibrates, erythromycin, immunosuppressants, antifungal drug (azole derivatives) a i ka hopena nikotinic ma nā ʻaina hypolipidemic (ʻoi aku ma mua o 1 g / lā), pono ke kumu kūpono i manaʻo ʻia a me nā hopena e hiki ke mālama ʻia. Pono kiaʻi pinepine ʻia nā mea maʻi i mea e ʻike ai i ka ʻehaʻeha a nāwaliwali o ka naʻau, ma mua o nā mahina mua o ka mālama ʻana a i nā manawa he hoʻonui i nā dosis o kekahi lāʻau lapaʻau. Inā loaʻa, pono e noʻonoʻo pono i ka hui ʻana i ka hoʻohana ʻana i kēia mau lāʻau i ka hoʻohaʻahaʻa i ka wā mua a me ka mālama mālama ʻana. ʻAʻole hoʻolako ʻia ka hoʻohana pinepine ʻana o ka atorvastatin a me ka waikawa fusidic; no laila, ʻoi aku ka haʻalele ʻana o ka atorvastatin i ka wā o ka mālama ʻana me ka waikawa fusidic. I kēlā mau kūlana, hiki ke hāpai ʻia ka hoʻonā wā maʻamau o ka hana CPK, ʻoiai ke pale ʻole ʻia kēlā me ke nānā ʻole i ka hoʻomohala ʻana i ka myopathy koʻikoʻi.

Ma mua o ka hoʻomaʻamaʻa

Pono e hoʻohana ʻia ka liprimar me ka makaʻala i nā mea maʻi me nā mea e ʻike mua ana i ka hoʻomohala ʻana o ka rhabdomyolysis. Pono e kāohi ʻia ka hana CPK i kēia mau hihia aʻe ma mua o ka hoʻomaka ʻana i ka therapy atorvastatin:

• huakaʻi renal function,
• hypothyroidism
• mau hoʻoili kino ʻōwili i ka mōʻaukala a i ʻole ka moʻolelo ʻohana,
• i hoʻihoʻi mua i ka hopena toxic o HMG-CoA reductase inhibitors (statins) a i ʻole ka fibrates ma ka io o ka ʻiʻo,
• ka mōʻaukala o ka pūpū a me / a me nā mea maʻi e ʻai i nā nui waiʻona,
• i nā mea maʻi i ʻoi aku o 70 mau makahiki, pono e nānā ʻia ka pono, e nānā ka ʻike, aia ka mea i loaʻa i kēia mau maʻi nā mea i manaʻo ʻia i ka hoʻomohala ʻana o ka rhabdomyolysis,
• kahi e hāpai ai i ka hoʻonui ʻia ʻana o ka kukuna plasma o atorvastatin, e like me ka hoʻopili ʻana me nā lāʻau ʻē aʻe. I kēlā mau kūlana, pono e loiloi ʻia ka hopena o ka pilikia / pōmaikaʻi a pono e mālama ʻia ke nānā ʻana i ka maʻi o ka maʻi. I ka hihia o ka hoʻonui nui ʻana i ka hana CPK (ʻoi aku ma mua o 5 mau manawa i ʻoi aku ma mua o VGN), ʻaʻole pono e hoʻomaka ka lāʻau atorvastatin.

Ke hoʻohana nei i ka lālani Liprimar, a me nā poʻe ʻē aʻe i paʻa aku ka hoʻemi hou ʻia o HMG-CoA reductase, nā hihia līnika o ka rhabdomyolysis me ka hiki ʻole o ka hana renal ka hopena no ka myoglobinuria. Hiki i ke kumu pilikia no ka rhabdomyolysis kahi mua i hana ʻole ʻia i mua o ka hana. Pono e hāʻawi ʻia kēlā mau maʻi e kiaʻi me ka mālama pono ʻana i ka mokuʻāina o ka ʻōnaehana musculoskeletal. Inā hele mai nā hōʻailona o ka myopathy a i ʻole nā ​​mea kūpono no ka hoʻomohala ʻana i ka ʻeha ʻole ma muli o ka rhabdomyolysis (no ka laʻana, ka maʻi nui ʻana o ka maʻi, ka hypotension arterial, nui o nā hōʻeha, nā hōʻeha, metabolic, endocrine a me ka wai-electrolyte haunaele, hana hoʻomāino ʻole ʻia), Liprimar hoʻopau loa.

Hoʻomaʻamaʻa ʻia nā mea maʻi e pono koke lākou e kūkā i ke kauka inā ʻaʻole i loaʻa ka ʻeha a i ʻole nā ​​nāwaliwali o ka naʻau, inā ua hele pū lākou me ka malaise a me ka maʻi maʻi.

Hoʻomaʻamaʻa aku ka Stroke ma o ka hōʻemi ʻana i ka Cholesterol Active

I kahi hōʻike retrospective o nā subtypes stroke i loko o nā poʻe maʻi me ka maʻi ʻalopona coronary, ka mea i loaʻa iā ia kahi hōʻeha a i ʻole ka hōʻea ʻana i ka ischemic attack, ma ka hana mua ka mea i loaʻa i ka atorvastatin ma ke kūkaʻi o 80 mg, he kūlana kiʻekiʻe o ka hemorrhagic stroke i hoʻomaopopo ʻia me ka poʻe maʻi e loaʻa ana i ka placebo. ʻO ka piʻi nui e ʻike ʻia i ka poʻe maʻi me ka mōʻaukala o ka hemorrhagic stroke a i ʻole ka lacunar infarction i ka hoʻomaka ʻana o ke kula. Ma kēia pūʻulu o nā mea maʻi, ʻo ka loiloi o ka pōmaikaʻi / a i ka wā e lawe ai i ka atorvastatin i kahi mahele ʻo 80 mg ʻaʻole i wehewehe maikaʻi ʻia, ma kēia ʻano, ma mua o ka hoʻomaka ʻana i ka maʻi, ka hopena hiki ke hoʻomohala i ka ʻōpū hemorrhagic i kēia mau mea maʻi e loiloi maikaʻi ʻia.

Ma hope o kahi loiloi kūikawā o kahi noiʻi hauoli e pili ana i ka poʻe 4731 nā mea maʻi me ka maʻi ʻaluna coronary nona ka hōʻeha a i ka weliweli ischemic attack (TIA) i loko o nā mahina 6 mau i hala i kuhikuhi ʻia ma atorvastatin 80 mg / lā, he kūlana kiʻekiʻe o nā ʻeha hemorrhagic i ka hui atorvastatin o 80 mg i hōʻike ʻia ka hui plasebo (55 ma ka atorvastatin hui kūlike 33 i ka hui plasebo). ʻO ka poʻe maʻi me ka ʻōpū hemorrhagic i ka manawa o ke komo ʻana i ke aʻo ʻana he kiʻekiʻe kiʻekiʻe ka nui no ka mau hou ʻana i ka ʻōpū hemorrhagic (7 ma ka hui atorvastatin e kūʻē 2 i ka hui plasebo). Eia naʻe, nā poʻe maʻi e loaʻa ana i ka atorvastatin 80 mg / lā he mau liʻiliʻi iki o nā hōʻeha o kekahi ʻano (265 kūlike 311) a me nā hanana cardiovascular liʻiliʻi (123 a 204).

ʻO ka maʻi māmā interstitial

I ka wā o ka mālamaʻana me kekahi mau HMG-CoA reductase inhibitors (statins), ka mea i ka wā e hoʻolako nei i nā manawa lōʻihi, ua hōʻike ʻia nā hihia o ka maʻi interstitial lung. ʻO ka dyspnea, kahi pākē hua ʻole, a me kahi hōʻemi i ka nui o ke olakino (ʻoi aku ka momona, ke kaumaha ʻana o ke kaupaona ʻana, a me ke ʻano o ka maʻi paha). Inā kānalua ka mea maʻi i ka maʻi māmā interstitial, pono e hoʻokaʻawale ke ʻano atorvastatin.

Ka hana Endocrine

Ke hoʻohana nei i nā inhibitors o ka HMG-CoA reductase (statins), me ka atorvastatin, ua loaʻa nā hihia o ka hemoglobin glycosylated (HbA1) a me ka hoʻomakeke ʻana i ka glucose glucose glucose. Eia naʻe, ʻoi aku ka liʻiliʻi o ka hopena o ka hyperglycemia ma mua o ke kaemi o ka hōʻemi ʻana i ka hopena o ka hopena vascular aʻo ka lawe ʻana i ka HMG-CoA reductase inhibitors (statins).

Hoʻopilikia i ka hiki ke hoʻokau i nā kaʻa

ʻAʻohe ʻikepili e pili ana i ka hopena o Liprimar i ka hiki ke hoʻokau i nā kaʻa a komo i nā hana e hana ʻino ʻia e pono ai ka piʻi ʻana o ka nānā a me ka wikiwiki o ka hopena psychomotor. Akā, ʻoiai ke hiki i ka hoʻomohala ʻana i ka dizziness, e akahele ʻia i kēia mau hana